Analyst Price Targets — OLMA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 9, 2026 3:59 pm | Emily Bodnar | H.C. Wainwright | $38.00 | $16.45 | StreetInsider | Olema Pharmaceuticals (OLMA) PT Lowered to $38 at H.C. Wainwright |
| February 10, 2026 9:11 pm | — | Stifel Nicolaus | $48.00 | $23.37 | TheFly | Olema Oncology initiated with a Buy at Stifel |
| January 7, 2026 10:18 am | — | Piper Sandler | $40.00 | $25.04 | TheFly | Olema Oncology initiated with an Overweight at Piper Sandler |
| January 7, 2026 5:49 am | Michael Yee | UBS | $45.00 | $25.04 | StreetInsider | UBS Starts Olema Pharmaceuticals (OLMA) at Buy |
| December 11, 2025 1:56 pm | — | Oppenheimer | $48.00 | $31.66 | TheFly | Olema Oncology price target raised to $48 from $45 at Oppenheimer |
| December 11, 2025 11:52 am | — | Goldman Sachs | $38.00 | $30.68 | TheFly | Olema Oncology price target raised to $38 from $26 at Goldman Sachs |
| December 11, 2025 11:41 am | Emily Bodnar | H.C. Wainwright | $45.00 | $32.22 | StreetInsider | Olema Pharmaceuticals (OLMA) PT Raised to $45 at H.C. Wainwright |
| December 10, 2025 7:20 pm | Michael Yee | Jefferies | $43.00 | $30.66 | TheFly | Olema Oncology price target raised to $43 from $30 at Jefferies |
| November 21, 2025 12:15 pm | — | Goldman Sachs | $26.00 | $22.01 | TheFly | Olema Oncology price target raised to $26 from $18 at Goldman Sachs |
| November 20, 2025 4:26 pm | — | Guggenheim | $40.00 | $22.16 | TheFly | Olema Oncology price target raised to $40 from $20 at Guggenheim |
Latest News for OLMA
Olema Pharmaceuticals (NASDAQ: OLMA - Get Free Report) and Ligand Pharmaceuticals (NASDAQ: LGND - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership. Earnings and Valuation This table compares Olema Pharmaceuticals
SG Americas Securities LLC bought a new stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 69,382 shares of the company's stock, valued at approximately $1,735,000. SG Americas Securities
SAN FRANCISCO, April 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 188,500 shares of the Company's…
Paradigm Biocapital Advisor increased its stake in Olema Pharmaceuticals by 750,000 shares in Q4 2025. The quarter-end value of the position rose by $122.09 million, reflecting the new purchase.
Olema Pharmaceuticals (OLMA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for OLMA.
U.S. House Trading
No House trades found for OLMA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.